Among the combination regimens fludarabine in combination with alemtuzumab (FluCam regimen) was first given to refractory CLL patients,48 showing that most infections occurred within the first 3 months, when CD4+ cells were at the lowest level. This evidence concerns the gene CD4 and infection.